Physiologically based pharmacokinetic modeling to guide dose optimization in obstetrical pharmacology clinical trials: a response - 24/12/24
Doi : 10.1016/j.ajog.2024.07.034
Joyce E.M. van der Heijden, MSc
Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
Saskia N. de Wildt, MD, PhD
Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Pediatric and Neonatal Intensive Care, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands
Rick Greupink, PharmD, PhD 
Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
Le texte complet de cet article est disponible en PDF.
| The authors report no conflict of interest. |
|
| This publication is based on research funded by the Bill & Melinda Gates Foundation (grant number: INV-023795). The findings and conclusions contained within this study are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. |
© 2024
Elsevier Inc. Tous droits réservés.
Vol 232 - N° 1
P. e23 - janvier 2025 Retour au numéro
Article précédent
- Physiologically based pharmacokinetic modeling for dose optimization clinical trials on prenatal steroids
- Karel Allegaert, Thomas Schmitz, Oliver Baud
- Beyond the initial success: enhancing remote postpartum hypertension management
- Hantong Hu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?